Welcome to our dedicated page for STANDARD BIOTOOLS news (Ticker: LAB), a resource for investors and traders seeking the latest updates and insights on STANDARD BIOTOOLS stock.
Overview
Standard BioTools Inc. (Nasdaq: LAB), previously known as Fluidigm Corporation, is a company specializing in the development, manufacturing, and commercialization of advanced biomedical research tools. The company focuses on delivering next-generation technologies that enable researchers to accelerate the discovery and development of new medicines through robust and repeatable insights in health and disease.
Core Technologies and Solutions
At the heart of Standard BioTools’ offerings are its proprietary mass cytometry and microfluidics platforms. These technologies empower biomedical scientists by providing high-throughput, automated, and precision-driven analytical solutions. The company's instruments and assays are designed to process small sample volumes with exceptional sensitivity, facilitating thousands of biochemical measurements in parallel. This capability is critical for applications in proteomics and genomics, where reproducible and precise data is essential for understanding complex biological systems.
Business Segments and Market Focus
The company is organized into key segments, notably the Proteomics and Genomics divisions. While its Proteomics segment remains a prominent revenue generator, the Genomics segment extends the utility of its technology to provide comprehensive insights into gene expression and molecular biology. Standard BioTools serves a diverse range of customers, including academic institutions, government laboratories, pharmaceutical and biotechnology companies, and clinical research organizations. This broad customer base reflects its commitment to supporting the most pressing needs in translational and clinical research.
Operational Excellence and Innovation
Standard BioTools is recognized for its emphasis on operational excellence and continuous innovation. The company leverages automation and streamlined workflows—such as advanced slide loaders and integrated software solutions—to reduce operational costs while enhancing throughput and data quality. These innovations not only simplify complex assay procedures but also ensure that researchers can obtain reliable, reproducible data efficiently.
Industry Impact and Competitive Landscape
In an increasingly competitive landscape, Standard BioTools differentiates itself through its comprehensive suite of standardized tools and its ability to execute high-content proteomics and spatial biology applications. Its technologies enable researchers to uncover detailed biomarker profiles with minimal sample requirements, which is particularly valuable in complex disease research. The company’s integrated customer solutions and emphasis on operational efficiency allow it to stand apart from competitors by providing a robust platform that addresses both academic and commercial research challenges.
Research Applications and Customer Benefits
The offerings from Standard BioTools facilitate a wide array of research applications such as oncology, immunology, and immunotherapy. By delivering tools that generate high-quality data, the company empowers customers to translate scientific discoveries into improved patient outcomes. Its platforms enable comprehensive protein and gene analysis, aiding in tasks from early-stage biomarker discovery to detailed mechanism-of-action studies in clinical trials. This positions Standard BioTools as a critical partner in the pursuit of innovative therapies and transformative breakthroughs in human health.
Commitment to Quality and Repeatability
Quality and repeatability are central to Standard BioTools’ mission. The company’s technologies are designed with precision and consistency in mind, supporting rigorous scientific inquiry and reducing the margin for error in high-stakes research environments. By adhering to the highest standards of data integrity, Standard BioTools builds trust within the scientific community and drives sustained value for its stakeholders.
Conclusion
Standard BioTools Inc. is a key player in the life sciences tools industry, offering innovative, high-throughput solutions that empower biomedical researchers worldwide. Its advanced platforms and steadfast commitment to quality provide a competitive edge in a dynamic market, supporting the global pursuit of improved health outcomes through faster and better medicine development.
Standard BioTools (NASDAQ: LAB) has announced its participation in three major investor conferences in March 2025. The company will present at TD Cowen's 45th Annual Healthcare Conference on March 3rd at 3:10 p.m. ET, attend investor meetings at the 2025 Leerink Partners Global Healthcare Conference on March 12th, and present at KeyBanc's 5th Annual Healthcare Forum on March 19th at 4:30 p.m. ET.
All presentations will be available via webcast on the company's Investor Relations website, with recordings archived at investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) reported its Q4 and full year 2024 financial results, with full-year pro forma combined revenue of $175.1 million. The company achieved significant operational improvements, including a 17% reduction in pro forma operating loss and 33% year-over-year improvement in adjusted EBITDA.
Key financial highlights include additional $10 million in operational cost reductions, totaling $90 million in synergies over 12 months, and a strong balance sheet with $295 million in cash and no material debt. The company expects to reach adjusted EBITDA positive in 2026.
Q4 2024 revenue was $46.7 million, down 9% year-over-year, with consumables revenue up 10%, instruments revenue down 25%, and services revenue down 16%. For fiscal year 2025, Standard BioTools projects revenue between $165-175 million, factoring in anticipated NIH funding pressures in Americas academic revenue.
Standard BioTools (NASDAQ: LAB) has announced its upcoming fourth quarter and full year 2024 earnings conference call, scheduled for February 26, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss financial results and operational progress.
Investors can join via phone using (888) 346-3970 for US domestic callers or (412) 902-4297 for international participants. A live webcast will be available on the company's Investor Relations page, with an archived version accessible afterward at investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) announced preliminary, unaudited revenue results for Q4 and the full year 2024.
For Q4, the company expects revenue of approximately $46.5 million, contributing to a full-year revenue of around $174 million. This meets the top end of their revised guidance, adjusted in Q2 to account for industry-wide challenges.
CEO Michael Egholm highlighted significant progress in reducing operating expenses through the implementation of Standard BioTools Business Systems (SBS). He emphasized the need for continued discipline and improvement. Looking ahead to 2025, the company aims to achieve further efficiencies from integration, enhancing their R&D and shifting revenues towards high-margin offerings.
Egholm expressed optimism about the company's strategy and team, aiming for long-term value for shareholders and customers. The company will report detailed financial results for Q4 and the full year 2024 later this quarter, along with their 2025 outlook.
The preliminary results are subject to completion of annual audit procedures and internal reviews.
Standard BioTools (NASDAQ: LAB) announced that its SomaScan Platform was instrumental in a Nature Medicine study examining semaglutide's effects on obesity treatment. The research, conducted by Novo Nordisk, analyzed approximately 6,400 human proteins across nearly 2,000 participants from two phase 3 trials.
The study revealed significant changes in protein biomarkers linked to metabolic pathways, providing new insights into semaglutide's biological mechanisms and potential broader health benefits. The SomaScan Technology demonstrated unique advantages, including mechanistic insights into proteins and pathways, reliable results across studies, and the potential to accelerate clinical development through a validated 27-protein predictor that detected cardiovascular benefits in smaller, shorter studies.
Standard BioTools (NASDAQ: LAB) announced that its President and CEO, Michael Egholm, PhD, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The event will be held from January 13th to 16th at the Westin St. Francis Hotel in San Francisco, CA. Dr. Egholm’s presentation is scheduled for January 16th, 2024, at 9:45 a.m. PT. A live audio webcast of the presentation will be accessible via the Investor Relations page on the company’s website. An archived recording will also be available for later access on the same page.
Standard BioTools (Nasdaq: LAB) has appointed Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and former Chief Operating Officer of Standard BioTools, brings nearly 30 years of healthcare and life sciences industry experience. Previously, he served as President of Milliken's Healthcare Division and held leadership positions at Pall and Danaher Throughout his career, Kim has completed over 40 transactions in healthcare, medical technology, and life sciences sectors. Concurrent with Kim's appointment, Jonathan Mickelsen has been promoted to Vice President & Chief Accounting Officer.
Standard BioTools (NASDAQ: LAB) has announced its management team's participation in two major investor conferences in November 2024. President and CEO Michael Egholm, PhD, will deliver corporate presentations at the UBS Global Healthcare Conference on November 12 at 1:15 p.m. PT and at the Jefferies London Healthcare Conference on November 19 at 8:30 a.m. GMT. The presentations will be webcast live on the company's Investor Relations page, with recordings archived at investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) reported Q3 2024 revenue of $45 million, down 5% year-over-year. The company achieved a 50% adjusted EBITDA improvement and 35% net loss improvement year-over-year. Key financial metrics include: consumables revenue up 13%, instruments revenue down 42%, and services revenue flat. The company maintains $368 million in cash and investments. Operating expenses decreased 18.5% to $55 million, while net loss improved to $26.9 million. The company has operationalized $80 million in merger synergies, expected to be fully realized in 2025, and reaffirmed FY2024 revenue guidance of $170-175 million.
Standard BioTools Inc. (NASDAQ: LAB) has announced its plans to report third quarter 2024 financial results on Wednesday, October 30, 2024, after market close. The company will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET on the same day to discuss the results and operational progress.
Interested individuals can join the call by dialing (888) 346-3970 for US domestic callers or (412) 902-4297 for international callers. A live audio webcast will be available on the company's Investor Relations page. The webcast will be archived for future access on Standard BioTools' Investor Relations page at investors.standardbio.com.
FAQ
What is the current stock price of STANDARD BIOTOOLS (LAB)?
What is the market cap of STANDARD BIOTOOLS (LAB)?
What is the primary focus of Standard BioTools Inc.?
What technologies does Standard BioTools utilize?
How does Standard BioTools serve the research community?
What are the main business segments of Standard BioTools?
How does the company differentiate itself from competitors?
What kind of research applications benefit from Standard BioTools' technologies?
Who are the key customers of Standard BioTools?
How does Standard BioTools ensure quality and repeatability in its platforms?
